SUNDANCE Trial: Phase II Trial of Sunitinib as Maintenance Therapy After Stereotactic Radiosurgery in Patients With 1-3 Newly Diagnosed Brain Metastases.

Trial Profile

SUNDANCE Trial: Phase II Trial of Sunitinib as Maintenance Therapy After Stereotactic Radiosurgery in Patients With 1-3 Newly Diagnosed Brain Metastases.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Brain metastases; Cancer
  • Focus Therapeutic Use
  • Acronyms SUNDANCE
  • Most Recent Events

    • 28 Sep 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 May 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 14 May 2012 Actual patient number is 14 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top